{"entity":{"id":"nct06229340","kind":"trial","name":"Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations","aka":["NТО-RAS"],"tldr":"A phase 2 trial in pancreatic cancer, run by N.N. Petrov National Medical Research Center of Oncology, now recruiting.","summary":"Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations is a phase 2, interventional study registered as NCT06229340 by N.N. Petrov National Medical Research Center of Oncology, with a registry enrolment figure of 20 participants, started 2023-10-03 and due to reach its primary completion in 2026-10-01. Interventions recorded: Leflunomide; The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab. Conditions listed: RAS Mutation; Ras (Kras or Nras) Gene Mutation; Colorectal Cancer Recurrent; Pancreas Cancer; Lung Cancer; Melanoma; Refractory Cancer. Primary outcome: Objective response rate. Sites: Russia. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06229340","url":"https://clinicaltrials.gov/study/NCT06229340"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06229340","phase":"2","setting":"New Therapeutic Approaches for Tumors With RAS Gene Mutations","sponsor":"N.N. Petrov National Medical Research Center of Oncology","participation":[{"nct":"NCT06229340","source":"https://clinicaltrials.gov/study/NCT06229340","fetchedAt":"2026-10-07T16:54:19.620Z","studySha256":"f179e70640daa5c63d34337711fd5dada17c48bbdff960350cc23009fa164a8f","overallStatus":"UNKNOWN","lastUpdatePosted":"2024-01-29","leadSponsor":"N.N. Petrov National Medical Research Center of Oncology","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"85 Years","sex":"ALL","healthyVolunteers":true,"hasEligibility":true,"enrolment":20,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["Russia"]}],"started":"2023-10-03","startedType":"actual","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06229340/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}